Partner Nate Lacktman was quoted in a Politico morning news roundup section titled “Trouble with Telemedicine Payments,” covering the troubles he’s seen from hospital systems about payment for telemedicine services.
In response to the growing need of non-face-to-face services that lack clear coverage, Lacktman suggests that hospital systems explore “capitated add-on payments [for the services] … that way, the provider is incentivized to use these e-consults as much as possible, without skewing the payer’s utilization risk, and without the provider risking cannibalizing its own in-person covered visits in lieu of these e-consults.”
In response to the growing need of non-face-to-face services that lack clear coverage, Lacktman suggests that hospital systems explore “capitated add-on payments [for the services] … that way, the provider is incentivized to use these e-consults as much as possible, without skewing the payer’s utilization risk, and without the provider risking cannibalizing its own in-person covered visits in lieu of these e-consults.”
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”